Preclinical M&S Track
Introduction to ADMET Predictor®
ADMET Predictor Overview
Predicting optimal scheduling of drug combinations in lung cancer xenografts using a population PK/PD model
Bevacizumab-pemetrexed/cisplatin is a first-line therapeutic for advanced nonsquamous non-small cell lung cancer.
Introduction to FIH/Phase 1 Track
Application of Modeling & Simulation in Phase 1
Confidence in FIH PBPK models
PBPK modeling, with verification of predictive performance first performed in preclinical species, is superior to empirical methods for...
How We Build & Validate Industrial Strength Models
A strong, reliable tool tailored to the particular demands of the relevant endpoint that will get you...
Using a population mechanistic TMDD model calibrated on preclinical monkey data to simulate first-in-human
Which dose to choose to elicit the desired effect (efficacy), without causing harm (safety)?
Using a population PK/PD model developed on phase I to select the dose for Phase II: an example with an IgG1 mAb
Dosing of 30 mg/kg Q4W could guarantee >90% inhibition of membrane-bound receptor for 9 in 10 individuals
The Role of Modeling & Simulation (M&S) in Regulatory Decision Making
M&S Roles in Determining Clinical Doses
HTPK: A bridge to Early Development
Develop a simplified early PK assessment tool for non DMPK experts
Model-Based Meta-Analysis of Anti-tuberculosis Regimen Efficacy in Relapsing Mouse Model Studies
Although temporarily eclipsed by the COVID-19 pandemic, tuberculosis (TB) remains the leading infectious disease-related cause of death in the world
Pharmacometrics in Phase 1: First in Human and Dose Selection for Phase 2
Drug development and Phase 1 studies
GastroPlus® DDI Standards Update Project
Creation of a GastroPlus® project starts with structure import using ADMET Predictor Module for both substrates and perpetrators
Designing Novel Compounds with Optimized Target Activity and ADMET Properties Using the AIDD™ Module
Goal – design compounds that have high potency at the primary target...
Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Elevations Using DILIsym Quantitative Systems Toxicology Modeling
Remdesivir, a monophosphoramidate prodrug of a nucleoside analog, has been granted Emergency Use Authorization in the U.S. for the treatment of...
Collaborative R&D Models to Drive Innovation
Generative chemistry engine with chemically intelligent transforms
Predicting the in vivo performance of BCS class II/IV drugs using a combined in vitro – in silico approach Case study: Albendazole and Albendazole sulfoxide
Use of in vitro biorelevant experimentation in combination with in silico PBPK modeling to accurately predict the plasma...
Revisiting MUT_RISK in ADMET Predictor®
A mutagen is a physical or chemical agent that changes the genetic material, usually DNA, thus increasing the frequency of mutations
Quantitative Systems Toxicology Identifies the Mechanism and Data Gaps for Evaluating the Hepatotoxicity of Compound V
Compound V is a small molecule with potential therapeutic benefits in patients with obesity.
Untold Stories of Data Curation – MDCK Data Curation & Modeling
MDCK is a popular mammalian cell line used to measure apparent permeability